RBO 1597
Alternative Names: RBO-1597Latest Information Update: 28 Apr 2024
At a glance
- Originator Rubedo Life Sciences
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatic fibrosis
- Discontinued Renal fibrosis
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Hepatic-fibrosis in USA
- 19 Oct 2022 Discontinued for Renal fibrosis in USA (unspecified route) (Rubedo Life Sciences website, October 2022)
- 23 Mar 2021 Fibrosis therapeutics is available for licensing as of 23 Mar 2021. https://www.rubedolife.com/contact-us/